MX2022001865A - Articulos y metodos para la administracion de agentes terapeuticos. - Google Patents

Articulos y metodos para la administracion de agentes terapeuticos.

Info

Publication number
MX2022001865A
MX2022001865A MX2022001865A MX2022001865A MX2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A
Authority
MX
Mexico
Prior art keywords
articles
methods
therapeutic agents
colon
therapeutic agent
Prior art date
Application number
MX2022001865A
Other languages
English (en)
Inventor
Carlo Giovanni Traverso
Robert S Langer
Joshua Korzenik
Christoph Winfried Johannes Steiger
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2022001865A publication Critical patent/MX2022001865A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen artículos y métodos para administrar un agente terapéutico a un sujeto; estos artículos y métodos pueden ser útiles, en algunos casos, para la administración de agentes terapéuticos al colon de un sujeto; en algunas modalidades, un artículo está configurado para liberar un agente inductor de secreción, por ejemplo, para estimular la liberación de fluidos intestinales; el artículo, en algunas modalidades, comprende un agente terapéutico de tal manera que la liberación estimulada de fluido intestinal aumenta la cantidad de agente terapéutico disponible para absorción por el colon; por ejemplo, en algunas modalidades, los artículos y métodos descritos en el presente documento promueven ventajosamente una mayor absorción de agentes terapéuticos en sujetos en comparación con agentes terapéuticos administrados tradicionalmente sin componentes adicionales tales como un agente inductor de secreción, en algunas modalidades, los artículos y métodos descritos en este documento pueden aumentar la motilidad del colon de un sujeto; el aumento de las contracciones y el movimiento de fluidos en el colon provocado por el aumento de la motilidad puede facilitar ventajosamente la disolución o absorción del agente terapéutico.
MX2022001865A 2019-08-12 2020-08-12 Articulos y metodos para la administracion de agentes terapeuticos. MX2022001865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885450P 2019-08-12 2019-08-12
PCT/US2020/045987 WO2021030474A1 (en) 2019-08-12 2020-08-12 Articles and methods for administration of therapeutic agents

Publications (1)

Publication Number Publication Date
MX2022001865A true MX2022001865A (es) 2022-03-11

Family

ID=74568588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001865A MX2022001865A (es) 2019-08-12 2020-08-12 Articulos y metodos para la administracion de agentes terapeuticos.

Country Status (11)

Country Link
US (2) US20210046011A1 (es)
EP (1) EP4013401A4 (es)
JP (1) JP2022544239A (es)
KR (1) KR20220046623A (es)
CN (1) CN114340615A (es)
AU (1) AU2020330542A1 (es)
BR (1) BR112022001645A2 (es)
CA (1) CA3148226A1 (es)
IL (1) IL290427A (es)
MX (1) MX2022001865A (es)
WO (1) WO2021030474A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200006161A1 (it) 2022-03-29 2023-09-29 Bilayer Therapeutics Inc Forms and compositions of sodium chenodeoxycholate
IT202200019725A1 (it) 2022-09-26 2024-03-26 Bilayer Therapeutics Inc Forme e composizioni del chenodeossicolato di sodio

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
AU2007323018B2 (en) * 2006-09-04 2011-02-03 Panacea Biotec Limited Programmable buoyant delivery technology
WO2010062863A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
EP3187171B1 (en) * 2012-04-30 2024-09-25 Tillotts Pharma AG A delayed release drug formulation
JP2015519403A (ja) * 2012-06-14 2015-07-09 エントレガ，インコーポレイテッド 活性剤送達のための粘膜付着性デバイス
CA3153463A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
EP2968187A4 (en) * 2013-03-14 2016-08-17 Therabiome Llc TARGETED ADMINISTRATION OF PROBIOTIC ORGANISMS AND / OR THERAPEUTIC AGENTS IN THE GASTROINTESTINAL TRACT
CN104739845A (zh) * 2013-12-26 2015-07-01 上海医学生命科学研究中心有限公司 鹅去氧胆酸及其用途
US20180193621A1 (en) * 2015-06-30 2018-07-12 Entrega Inc. Device for oral delivery of active agents

Also Published As

Publication number Publication date
JP2022544239A (ja) 2022-10-17
AU2020330542A1 (en) 2022-02-17
KR20220046623A (ko) 2022-04-14
IL290427A (en) 2022-04-01
CN114340615A (zh) 2022-04-12
US20210046011A1 (en) 2021-02-18
EP4013401A1 (en) 2022-06-22
EP4013401A4 (en) 2023-07-12
WO2021030474A1 (en) 2021-02-18
BR112022001645A2 (pt) 2022-05-03
CA3148226A1 (en) 2021-02-18
US20220202721A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
MX2022001865A (es) Articulos y metodos para la administracion de agentes terapeuticos.
AR110299A1 (es) Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
JO3709B1 (ar) تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
DE602008006700D1 (es)
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX2013012206A (es) Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas.
MX2018000258A (es) Dispositivo de suministro de un solo uso.
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
MX2019008482A (es) Tratamiento medico que comprende administracion enteral de edaravona.
MX2013012204A (es) Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2013012205A (es) Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
AR104177A1 (es) Sistema para la administración de fármacos en la glándula lagrimal
TN2015000480A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias